You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 251 No. 15, April 20, 1984 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (24)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Serological Response to Rubella Revaccination

Mary K. Serdula, MD; Scott B. Halstead, MD; Ned H. Wiebenga, MD; Kenneth L. Herrmann, MD

JAMA. 1984;251(15):1974-1977.


Abstract

To document the serological response, 21 seronegative rubella vaccinees (hemagglutination inhibition [HI] titer <10) were revaccinated with RA 27/3 rubella vaccine. All demonstrated an anamnestic response. Although RA 27/3 vaccine was an effective booster, antibody boost was not maintained in some persons. Of 15 persons tested, 24 to 27 months after revaccination, six had a significant HI antibody drop (fourfold or greater); only one had lost all detectable HI antibody. Although all 21 study participants were initially HI seronegative by rubella HI testing, 16 (76.2%) possessed neutralization and/or enzyme-linked immunosorbent assay antibodies before revaccination. As more persons with vaccine-induced immunity join the adult population pool, more sensitive test methods may be needed to assess serological status accurately.

(JAMA 1984;251:1974-1977)



Author Affiliations

From the Division of Field Services, Epidemiology Program Office (Dr Serdula), and the Division of Viral Diseases, Center for Infectious Diseases (Dr Herrmann), Centers for Disease Control, Atlanta; and the School of Tropical Medicine, University of Hawaii, Honolulu (Dr Halstead).


Footnotes

{dagger}Deceased. Dr Wiebenga was formerly with the Hawaii Department of Health, Honolulu.

The use of trade names is for identification only and does not imply endorsement by the US Department of Health and Human Services or the Public Health Service.

Reprint requests to Division of Nutrition, Center for Health Promotion and Education, Centers for Disease Control, Atlanta, GA 30333 (Dr Serdula).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Identifying Risk Factors for Rubella Susceptibility in a Population at Risk in the United States
Danovaro-Holliday et al.
AJPH 2003;93:289-291.
FULL TEXT  

Rubella Antibody Persistence After Immunization: Sixteen-Year Follow-up in the Hawaiian Islands
Chu et al.
JAMA 1988;259:3133-3136.
ABSTRACT  

Some Current Issues Relating to Rubella Vaccine
Preblud
JAMA 1985;254:253-256.
ABSTRACT  

Rubella Prevention: Recommendation of the Immunization Practices Advisory Committee
ANN INTERN MED 1984;101:505-513.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.